

Publications Cimi-Paris

2014

N = 96

Dec 2014

1. **Amiel C**, Schneider V, Guessant S, Hamidi M, Kherallah K, Lebrette MG, Chas J, Lependeven C, **Pialoux G**. [Initiation of rilpivirine, tenofovir and emtricitabine \(RPV/TDF/FTC\) regimen in 363 patients with virological vigilance assessment in 'real life'](#). J Antimicrob Chemother. 2014 Dec;69(12):3335-9.
2. Hill BJ, Darrah PA, Ende Z, Ambrozak DR, Quinn KM, Darko S, Gostick E, Wooldridge L, van den Berg HA, Venturi V, **Larsen M**, Davenport MP, Seder RA, Price DA, Douek DC. [Epitope specificity delimits the functional capabilities of vaccine-induced CD8 T cell populations](#). J Immunol. 2014 Dec 1;193(11):5626-36.
3. **Lescar J**, Meyer I, Akshita K, Srinivasaraghavan K, Verma C, Palous M, **Mazier D**, Datry A, **Fekkar A**. [Aspergillus fumigatus harbouring the sole Y121F mutation shows decreased susceptibility to voriconazole but maintained susceptibility to itraconazole and posaconazole](#). J Antimicrob Chemother. 2014 Dec;69(12):3244-7. doi: 10.1093/jac/dku316. Epub 2014 Aug 13.
4. S. Bialek-Davenet, A. Criscuolo, F. Ailloud, V. Passet, M.-H. Nicolas-Chanoine, **D. Decré**, et S. Brisse, [Development of a multiplex PCR assay for identification of Klebsiella pneumoniae hypervirulent clones of capsular serotype K2](#). J. Med. Microbiol., vol. 63, n° Pt 12, p. 1608-1614, Dec. 2014.
5. **F. Compain**, **A. Babosan**, S. Brisse, N. Genel, **J. Audo**, F. Ailloud, **N. Kassis-Chikhani**, **G. Arlet**, et **D. Decré**, [Multiplex PCR for detection of seven virulence factors and K1/K2 capsular serotypes of Klebsiella pneumoniae](#). J. Clin. Microbiol., vol. 52, n° 12, p. 4377-4380, dec. 2014.
6. E. Liapis, A. Pantel, **J. Robert**, M.-H. Nicolas-Chanoine, L. Cavalié, N. van der Mee-Marquet, C. de Champs, N. Aissa, C. Eloy, V. Blanc, C. Guyeux, D. Hocquet, J.-P. Lavigne, X. Bertrand, et ONERBA, « [Molecular epidemiology of OXA-48-producing Klebsiella pneumoniae in France](#) », Clin. Microbiol. Infect., vol. 20, n° 12, p. O1121-1123, dec. 2014.
7. C. Pontoizeau, L. Dangers, **V. Jarlier**, C. E. Luyt, E. Guiller, M. H. Fievet, M. Lecsö-Bornet, **A. Aubry**, et **F. Brossier**, [Ruling out false-positive urinary Legionella pneumophila serogroup 1 and Streptococcus pneumoniae antigen test results by heating urine.](#), J. Clin. Microbiol., vol. 52, n° 12, p. 4347-4349, Dec. 2014.
8. **A. Renvoisé**, **C. Bernard**, **N. Veziris**, E. Galati, **V. Jarlier**, et **J. Robert**, [Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare.](#), J. Clin. Microbiol., vol. 52, n° 12, p. 4439-4440, Dec. 2014.

Nov 2014

9. Khan ME, Borde C, Rocha EP, Mériaux V, **Maréchal V**, Escoll P, Goyard S, Cavaillon JM, Manoury B, Doyen N. [TLR9 activation is triggered by the excess of stimulatory versus inhibitory motifs present in Trypanosomatidae DNA](#). PLoS Negl Trop Dis. 2014 Nov 13;8(11):e3308. doi: 10.1371/journal.pntd.0003308. eCollection 2014 Nov.
10. Fabre-Mersseman V, Tubiana R, **Papagno L**, Bayard C, Briceno O, **Fastenackels S**, Dudoit Y, Rostane H, Salmon D, Costagliola D, Caby F, **Sauce D**, Viard JP, **Appay V**. [Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy](#). AIDS. 2014 Nov 28;28(18):2677-82.
11. **Soria A**, **Boccaro D**, Chonco L, **Yahia N**, **Dufossée M**, **Cardinaud S**, **Moris A**, Liard C, Joulin-Giet A, Julithe M, Mimoun M, **Combadière B**, **Perrin H**. [Long-term maintenance of skin immune system in a NOD-Scid IL2ry\(null\) mouse model transplanted with human skin](#). Exp Dermatol. 2014 Nov;23(11):850-2.
12. Ostuni MA, **Guellec J**, **Hermand P**, Durand P, **Combadière C**, Pincet F, **Deterre P**. [CX3CL1, a chemokine finely tuned to adhesion: critical roles of the stalk glycosylation and the membrane domain](#). Biol Open. 2014 Nov 13;3(12):1173-82.

13. Van Schaijk BC, Ploemen IH, Annoura T, Vos MW, Lander F, van Gemert GJ, Chevalley-Maurel S, van de Vegte-Bolmer M, Sajid M, **Franetich JF**, **Lorthiois A**, Leroux-Roels G, Meuleman P, Hermesen CC, **Mazier D**, Hoffman SL, Janse CJ, Shahid KM, Sauerwein RW. [A genetically attenuated malaria vaccine candidate based on *P. falciparum* b9/slarp gene-deficient sporozoites.](#) *Elife.* 2014 Nov 19;3.
14. **A. Bousquet**, **M. Duprilot**, D. Moissenet, B. Salauze, J. Rambaud, **N. Genel**, H. Vu-Thien, **G. Arlet**, et **D. Decré**, [First case of multidrug-resistant blaNDM-1- and blaOXA-232-carrying *Klebsiella pneumoniae* and its probable cross-transmission in a French hospital.](#), *Int J Antimicrob Agents.* 2014 Nov;44(5):469-70.

Oct 2014

15. **Rodero MP**, Licata F, Poupel L, **Hamon P**, Khosrotehrani K, **Combadiere C**, **Boissonnas A**. [In vivo imaging reveals a pioneer wave of monocyte recruitment into mouse skin wounds.](#) *PLoS One.* 2014 Oct 1;9(10):e108212. doi: 10.1371/journal.pone.0108212. eCollection 2014
16. **Risco-Castillo V**, **Topçu S**, **Son O**, **Briquet S**, **Manzoni G**, **Silvie O**. [CD81 is required for rhoptry discharge during host cell invasion by *Plasmodium yoelii* sporozoites.](#) *Cell Microbiol.* 2014 Oct;16(10):1533-48.
17. M. A. Jure, **M. Duprilot**, H. E. Musa, C. López, M. C. de Castillo, F. X. Weill, **G. Arlet**, et **D. Decré**, [Emergence of KPC-2-Producing *Salmonella enterica* Serotype Schwarzengrund in Argentina.](#) *Antimicrob. Agents Chemother.*, vol. 58, n° 10, p. 6335-6336, oct. 2014.
18. **J. Robert**, A. Pantel, A. Mérens, J.-P. Lavigne, M.-H. Nicolas-Chanoine, et ONERBA's Carbapenem Resistance Study Group, [Incidence rates of carbapenemase-producing *Enterobacteriaceae* clinical isolates in France: a prospective nationwide study in 2011-12.](#), *J. Antimicrob. Chemother.*, vol. 69, n° 10, p. 2706-2712, oct. 2014.
19. Chauvat A, Benhamouda N, Gey A, **Lemoine FM**, Paulie S, Carrat F, Gougeon ML, Rozenberg F, Krivine A, Cherai M, Lehmann P 5th, Quintin-Colonna F, Launay O, Tartour E. [Clinical validation of IFN \$\gamma\$ /IL-10 and IFN \$\gamma\$ /IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans.](#) *Hum Vaccin Immunother.* 2014;10(1):104-13.
20. **Moris A**, **Murray S** and **Cardinaud S**. [AID and APOBECs span the gap between innate and adaptive immunity.](#) *Frontiers in Microbiology*, 2014 Oct 13;5:534.

Sept 2014

21. Frobert E, **Burrel S**, Ducastelle-Lepretre S, Billaud G, Ader F, Casalegno JS, Nave V, **Boutolleau D**, Michallet M, Lina B, Morfin F. [Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France.](#) *Antiviral Res.* 2014 Nov;111:36-41. doi: 10.1016/j.antiviral.2014.08.013. Epub 2014 Sep 8.
22. Pilorgé L, **Burrel S**, Aït-Arkoub Z, **Agut H**, **Boutolleau D**. [Human cytomegalovirus \(CMV\) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism.](#) *Antiviral Res.* 2014 Nov;111:8-12. doi: 10.1016/j.antiviral.2014.08.014. Epub 2014 Sep 4.
23. Smolen KK, Cai B, Gelinas L, Fortuno ES 3rd, **Larsen M**, Speert DP, Chamekh M, Cooper PJ, Esser M, Marchant A, Kollmann TR. [Single-cell analysis of innate cytokine responses to pattern recognition receptor stimulation in children across four continents.](#) *J Immunol.* 2014 Sep 15;193(6):3003-12.
24. Bourdin C, Busse A, Kouamou E, Touafek F, Bodaghi B, Le Hoang P, **Mazier D**, Paris L, **Fekkar A**. [PCR-based detection of *Toxoplasma gondii* DNA in blood and ocular samples for diagnosis of ocular toxoplasmosis.](#) *J Clin Microbiol.* 2014 Nov;52(11):3987-91. doi: 10.1128/JCM.01793-14. Epub 2014 Sep 10.
25. Imbert S, Palous M, Meyer I, Dannaoui E, **Mazier D**, Datry A, **Fekkar A**. [In vitro combination of voriconazole and miltefosine against clinically relevant molds.](#) *Antimicrob Agents Chemother.* 2014 Nov;58(11):6996-8.
26. **Fekkar A**, **Dannaoui E**, Meyer I, Imbert S, **Brossas JY**, Uzunov M, Mellon G, **Nguyen S**, Guiller E, **Caumes E**, **Leblond V**, **Mazier D**, Fievet MH, Datry A. [Emergence of echinocandin-resistant *Candida* spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?](#) *Eur J Clin Microbiol Infect Dis.* 2014 Sep;33(9):1489-96.
27. **A. Renvoisé**, A. I. Bagnis, et **A. Aubry**, [\[Antimicrobial prophylaxis for preventing recurrent](#)

- [urinary tract infections in non-pregnant women: pros and cons](#)], Rev Prat, vol. 64, n° 7, p. 972-973, sept. 2014.
28. **Petit NY**, Lambert-Niclot S, Marcelin AG, Garcia S, **Marodon G**. [Targeting both viral and host determinants of human immunodeficiency virus entry, using a new lentiviral vector coexpressing the T20 fusion inhibitor and a selective CCL5 intrakine](#). Hum Gene Ther Methods. 2014 Aug;25(4):232-40. doi: 10.1089/hgtb.2014.034.
 29. **F. Brossier**, C. Sola, G. Millot, **V. Jarlier**, **N. Veziris**, et **W. Sougakoff**, [Comparison of a semiautomated commercial repetitive-sequence-based PCR method with spoligotyping, 24-locus mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing, and restriction fragment length polymorphism-based analysis of IS6110 for Mycobacterium tuberculosis typing](#). J. Clin. Microbiol., sept. 2014, 52(11):4082-6.
 30. **Petitdemange C**, **Wauquier N**, Jacquet JM, **Theodorou I**, Leroy E, **Vieillard V**. [Association of HLA class-I and inhibitory KIR genotypes in Gabonese patients infected by Chikungunya or Dengue type-2 viruses](#). PLoS One. 2014 Sep 29;9(9):e108798.
 31. Imwong M, Hanchana S, Malleret B, Rénia L, Day NPJ, Dondorp A, Nosten F, **Snounou G** & White NJ. [High-throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias](#). J Clin Microbiol. 2014 Sep;52(9):3303-9.
 32. Leclerc A, Chavatte J-M, Landau I, **Snounou G** & Petit T (2014). [Morphologic and molecular study of hemoparasites in wild corvids and evidence of sequence identity with Plasmodium DNA detected in captive black-footed penguins \(Spheniscus demersus\)](#). J Zoo Wildl Med. 2014 Sep;45(3):577-88.
 33. **A. Renvoisé**, C. I. Bagnis, et **A. Aubry**, [\[Antimicrobial prophylaxis for preventing recurrent urinary tract infections in non-pregnant women: pros and cons\]](#). Rev Prat. 2014 Sep;64(7):972-3.
- Aug 2014**
34. Boyd A, **Gozlan J**, Maylin S, Delaugerre C, Peytavin G, Girard PM, Zoulim F, Lacombe K. [Persistent viremia in human immunodeficiency virus/hepatitis B coinfecting patients undergoing long-term tenofovir: virological and clinical implications](#). Hepatology. 2014 Aug;60(2):497-507.
 35. Cheraï M, Hamel Y, **Baillou C**, Touil S, Guillot-Delost M, Charlotte F, Kossir L, Simonin G, Maury S, Cohen JL, **Lemoine FM**. [Generation of human alloantigen-specific regulatory T-cells under good manufacturing practice-compliant conditions for cell therapy](#). Cell Transplant. 2014 Aug 5.
 36. Cufi P, **Soussan P**, Truffault F, Fetouchi R, Robinet M, Fadel E, Berrih-Aknin S, Le Panse R. [Thymoma-associated myasthenia gravis: On the search for a pathogen signature](#). J Autoimmun. 2014 Aug;52:29-35.
 37. S. Godreuil, N. Leban, A. Padilla, R. Hamel, N. Luplertlop, **A. Chauffour**, M. Vittecoq, F. Hoh, F. Thomas, **W. Sougakoff**, C. Lionne, **H. Yssel**, et D. Missé, [Aedesin: structure and antimicrobial activity against multidrug resistant bacterial strains](#). PLoS One. 2014 Aug 27;9(8):e105441..
- Jul 2014**
38. Campillo-Gimenez L, Casulli S, Dudoit Y, Seang S, **Carcelain G**, Lambert-Niclot S, **Appay V**, **Autran B**, Tubiana R, **Elbim C**. [Neutrophils in antiretroviral therapy-controlled HIV demonstrate hyperactivation associated with a specific IL-17/IL-22 environment](#). J Allergy Clin Immunol. 2014 Nov;134(5):1142-52.e5. doi: 10.1016/j.jaci.2014.05.040. Epub 2014 Jul 16.
 39. de Masson A, Kirilovsky A, **Zoorob R**, Avettand-Fenoel V, Morin V, Oudin A, Descours B, Rouzioux C, **Autran B**. [Blimp-1 overexpression is associated with low HIV-1 reservoir and transcription levels in central memory CD4+ T cells from elite controllers](#). AIDS. 2014 Jul 17;28(11):1567-77..
 40. Brousse V, **Buffet P**, Rees D. [The spleen and sickle cell disease: the sick\(led\) spleen](#). Br J Haematol. 2014 Jul;166(2):165-76.
 41. **Jauréguiberry S**, **Ndour PA**, **Roussel C**, Ader F, Safeukui I, Nguyen M, **Biligui S**, **Cicéron L**, **Mouri O**, **Kendjo E**, Bricaire F, Vray M, Angoulvant A, Mayaux J, Haldar K, **Mazier D**, Danis M, **Caumes E**, **Thellier M**, **Buffet P**; French Artesunate Working Group. [Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins](#). Blood. 2014 Jul 10;124(2):167-75.
 42. **Bonduelle O**, Carrat F, Luyt C-E, Lepout C, Mosnier A, Benhabiles N, Krivine A, Rozenberg F,

- Yahia N, Samri A**, Rousset D, van der Werf S, **Autran B, Combadiere B**, [Characterization of pandemic influenza immune memory signature after vaccination or infection](#). J Clin Invest. 2014 Jul;124(7):3129-36.
43. T. V. Bui, V. Meyssonnier, P. Y. Boelle, D. Che, D. Antoine, **V. Jarlier**, et **J. Robert**, [Decrease in the incidence of culture-positive meningitis and cerebral tuberculomas in France from 1990 to 2007](#), Epidemiol. Infect., vol. 142, n° 7, p. 1510-1516, jul. 2014.
44. Sun X, Fujiwara M, Shi Y, Kuse N, Gatanaga H, **Appay V**, Gao GF, Oka S, Takiguchi M. [Superimposed epitopes restricted by the same HLA molecule drive distinct HIV-specific CD8+ T cell repertoires](#). J Immunol. 2014 Jul 1;193(1):77-84..
45. F. Compain, L. Frangeul, **L. Drieux**, C. Verdet, S. Brisse, **G. Arlet**, et **D. Decré**, [Complete nucleotide sequence of two multidrug-resistant IncR plasmids from Klebsiella pneumoniae](#), Antimicrob Agents Chemother. 2014 Jul;58(7):4207-10.
46. Bieber T, Chosidow O, Bodsworth N, Tyring S, Hercogova J, Bloch M, Davis M, Lewis M, **Boutolleau D**, Attali P. [Efficacy and safety of aciclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes \(LIP Trial\): a double-blind, placebo-controlled, self-initiated trial](#). J Drugs Dermatol. 2014 Jul;13(7):791-8.
47. Pedergrana V, Syx L, Cobat A, Guergnon J, Brice P, Ferme C, Carde P, Hermine O, Pendeven CL, **Amiel C**, Taoufik Y, Alcais A, **Theodorou I**, Besson C, Abel L. [Combined linkage and association studies show that HLA class II variants control levels of antibodies against Epstein-Barr virus antigens](#). PLoS One. 2014 Jul 15;9(7):e102501.
48. Tan JJJ, Capozzoli M, Sato M, Watthanaworawit W, Ling CL, Mauduit M, Malleret B, Grüner AC, Tan R, Nosten FH, **Snounou G**, Rénia L & Ng. [An integrated lab-on-chip for rapid identification and simultaneous differentiation of tropical pathogens](#). LFP, 2014, [PLoS Negl Trop Dis](#). 2014 Jul 31;8(7):e3043.
49. **A. Renvoisé, S. Pang, C. Bernard, F. Brossier, N. Veziris, E. Capton, V. Jarlier, et W. Sougakoff**, [First Whole-Genome Sequence of a Clinical Isolate of Multidrug-Resistant Mycobacterium bovis BCG](#). Genome Announc. 2014 Jul 10;2(4). pii: e00611-14.
50. M. Monié, **L. Drieux**, B. Nzili, M. Dicko, C. Goursot, S. Greffard, **D. Decré**, et A. Mézière, [Klebsiella pneumoniae necrotizing fasciitis of the leg in an elderly French woman](#). Clin Interv Aging. 2014 Jul 18;9:1171-4.
51. A. Ycart et **N. Veziris**, [Unbiased estimation of mutation rates under fluctuating final counts](#). PLoS One. 2014 Jul 2;9(7):e101434.

Jun 2014

52. Deback C, **Burrel S**, Varnous S, **Carcelain G**, Conan F, Aït-Arkoub Z, **Autran B**, Gandjbakhch I, **Agut H, Boutolleau D**. [Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature](#). Antivir Ther. 2014 Jun 25..
53. **Appay V, Sauce D**. [Naive T cells: The crux of cellular immune aging?](#) Exp Gerontol. 2014 Jun;54C:90-93.
54. **Mouri O**, Morizot G, Van der Auwera G, Ravel C, Passet M, Chartrel N, Joly I, **Thellier M, Jauréguiberry S, Caumes E, Mazier D, Marinach-Patrice C, Buffet P**. [Easy identification of leishmania species by mass spectrometry](#). PLoS Negl Trop Dis. 2014 Jun 5;8(6):e2841.
55. Mann JF, McKay PF, Fiserova A, Klein K, Cope A, Rogers P, Swales J, Seaman MS, **Combadiere B**, Shattock RJ. [Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes](#). J Virol. 2014 Jun;88(12):6959-69.
56. **Jauréguiberry S, Thellier M, Mazier D**, Lebrun-Vigne B, Bricaire F, **Buffet P**, Caumes E. [L-17: L'artésunate IV est efficace et bien tolérée malgré la fréquente et rarement sévère anémie hémolytique retardée : suivi prospectif de 123 malades atteints de paludisme grave traités en France](#). Med Mal Infect. 2014 Jun;44(6 Suppl):64..
57. Robinet P, **Baychelier F**, Fontaine T, Picard C, **Debré P, Vieillard V**, Latgé JP, **Elbim C**. [A polysaccharide virulence factor of a human fungal pathogen induces neutrophil apoptosis via NK cells](#). J Immunol. 2014 Jun 1;192(11):5332-42.

May 2014

58. Godet AN, Soignon G, Koubi H, **Bonafous P**, **Agut H**, Poirot C, **Gautheret-Dejean A**. [Presence of HHV-6 genome in spermatozoa in a context of couples with low fertility: what type of infection?](#) *Andrologia*. 2014 May 20. doi: 10.1111/and.12299.
59. Guihot A, Luyt CE, Parrot A, Rousset D, Cavaillon JM, Boutolleau D, Fitting C, Pajanirassa P, Mallet A, Fartoukh M, **Agut H**, Musset L, **Zoorob R**, Kirilovsky A, **Combadière B**, van der Werf S, **Autran B**, **Carcelain G**; FluBAL Study Group. [Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A\(H1N1\) 2009 infection.](#) *Am J Respir Crit Care Med*. 2014 May 15;189(10):1240-9.
60. Ben Salah A, Zaâtour A, Ben Messaoud N, Kidar A, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Nielsen CJ, Novitt-Moreno A, Ransom JH, Morizot G, Grogl M, **Buffet PA**. [Parasite load decrease during application of a safe and easily applied antileishmanial aminoglycoside cream.](#) *PLoS Negl Trop Dis*. 2014 May 22;8(5):e2749.
61. **Petitdémange C**, **Wauquier N**, Rey J, Hervier B, Leroy E, **Vieillard V**. [Control of acute dengue virus infection by natural killer cells.](#) *Front Immunol*. 2014 May 13;5:209.
62. Compain, A. Poisson, S. Le Hello, C. Branger, F.-X. Weill, **G. Arlet**, et **D. Decré**, [Targeting relaxase genes for classification of the predominant plasmids in Enterobacteriaceae.](#), *Int. J. Med. Microbiol.*, vol. 304, n° 3-4, p. 236-242, mai 2014.
63. Annoura T, van Schaijk BC, Ploemen IH, Sajid M, Lin JW, Vos MW, Dinmohamed AG, Inaoka DK, Rijpma SR, van Gemert GJ, Chevalley-Maurel S, Kielbasa SM, Scheltinga F, Franke-Fayard B, Klop O, Hermsen CC, Kita K, Gego A, **Franetich JF**, **Mazier D**, Hoffman SL, Janse CJ, Sauerwein RW, Khan SM. [Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development.](#) *FASEB J*. 2014 May;28(5):2158-70.
64. Ablashi D, **Agut H**, Alvarez-Lafuente R, Clark DA, Dewhurst S, Diluca D, Flamand L, Frenkel N, Gallo R, Gompels UA, Hollsborg P, Jacobson S, Luppi M, Lusso P, Malnati M, Medveczky P, Mori Y, Pellett PE, Pritchett JC, Yamanishi K, Yoshikawa T. [Classification of HHV-6A and HHV-6B as distinct viruses.](#) *Arch Virol*. 2014 May;159(5):863-70..

Apr 2014

65. **Mathian A**, **Miyara M**, **Gorochov G**. [Proteome-wide analysis and CXCL4 in systemic sclerosis.](#) *N Engl J Med*. 2014 Apr 17;370(16):1562.
66. Grütze J, Rindte K, Goosmann C, **Silvie O**, Rauch C, Heuer D, Lehmann MJ, Mueller AK, Brinkmann V, Matuschewski K, Ingmundson A. [The spatiotemporal dynamics and membranous features of the Plasmodium liver stage tubovesicular network](#) *Traffic*. 2014 Apr;15(4):362-82.
67. **Manzoni G**, **Briquet S**, Risco-Castillo V, Gaultier C, **Topçu S**, Ivănescu ML, **Franetich JF**, Hoareau-Coudert B, **Mazier D**, **Silvie O**. [A rapid and robust selection procedure for generating drug-selectable marker-free recombinant malaria parasites.](#) *Sci Rep*. 2014 Apr 23;4:4760.
68. Ibrahim N, Ibrahim H, Dormoi J, Briolant S, Pradines B, **Moreno A**, **Mazier D**, Legrand P, Nepveu F. [Albumin-bound nanoparticles of practically water-insoluble antimalarial lead greatly enhance its efficacy.](#) *Int J Pharm*. 2014 Apr 10;464(1-2):214-24.
69. **Achour A**, **Baychelier F**, Marty M, **Debré P**, Samuel D, **Vieillard V**. [Transplantation-induced cancers: Emerging evidence that clonal CMV-specific NK cells are causal immunogenic factors.](#) *Oncoimmunology*. 2014 Apr 29;3:e28782. eCollection 2014.
70. **Burrel S**, Rouard C, **Boutolleau D**. [Helicase-primase inhibitor pritelivir for HSV-2 infection.](#) *N Engl J Med*. 2014 Apr 24;370(17):1663-4.

Mar 2014

71. N'dilimabaka N, Taoufiq Z, Zougbedé S, **Bonnefoy S**, **Lorthiois A**, Couraud PO, **Rebollo A**, **Snounou G**, **Mazier D**, **Moreno-Sabater A**. [P. falciparum isolate-specific distinct patterns of induced apoptosis in pulmonary and brain endothelial cells.](#) *PLoS One*. 2014 Mar 31;9(3):e90692.
72. Dembélé L, **Franetich JF**, **Lorthiois A**, Gego A, Zeeman AM, Kocken CH, Le Grand R, Dereuddre-Bosquet N, van Gemert GJ, Sauerwein R, Vaillant JC, Hannoun L, Fuchter MJ, Diagana TT, Malmquist NA, Scherf A, **Snounou G**, **Mazier D**. [Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures.](#) *Nat Med*. 2014 Mar;20(3):307-12.
73. Hattab S, **Guihot A**, Guiguet M, **Fourati S**, **Carcelain G**, Caby F, Marcelin AG, **Autran B**, Costagliola D, Katlama C. [Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1](#)

- [infection: an observational study](#). BMC Infect Dis. 2014 Mar 4;14:122.
74. Blum J, **Buffet P**, Visser L, Harms G, Bailey MS, Caumes E, Clerinx J, van Thiel PP, Morizot G, Hatz C, Dorlo TP, Lockwood DN. [LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014](#). J Travel Med. 2014 Mar-Apr;21(2):116-29.
 75. Offeddu V, Rauch M, **Silvie O**, Matuschewski K. [The Plasmodium protein P113 supports efficient sporozoite to liver stage conversion in vivo](#). Mol Biochem Parasitol. 2014 Mar 20;193(2):101-109.
 76. **Silvie O, Briquet S**, Müller K, **Manzoni G**, Matuschewski K. [Post-transcriptional silencing of UIS4 in Plasmodium berghei sporozoites is important for host switch](#). Mol Microbiol. 2014 Mar;91(6):1200-13.
 77. Régent A, **Autran B, Carcelain G**, Cheynier R, Terrier B, Charmeteau-De Muylder B, Krivitzky A, Oksenhendler E, Costedoat-Chalumeau N, Hubert P, Lortholary O, Dupin N, **Debré P**, Guillevin L, Mouthon L. French Idiopathic CD4 T Lymphocytopenia Study Group. [Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients](#). Medicine (Baltimore). 2014 Mar;93(2):61-72.
 78. C.-E. Luyt, **A. Aubry**, Q. Lu, M. Micaelo, N. Bréchet, **F. Brossier**, H. Brisson, J.-J. Rouby, J.-L. Trouillet, A. Combes, **V. Jarlier**, et J. Chastre, [Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia](#). Antimicrob. Agents Chemother., vol. 58, n° 3, p. 1372-1380, mars 2014.
 79. S. Brisse, C. Brehony, T. Conceição, M. Cubero, C. Glasner, M. Le Gouil, **A. Renvoisé**, S. Sheppard, et L. A. Weinert, [Microbial molecular markers and epidemiological surveillance in the era of high throughput sequencing: an update from the IMMEM-10 conference](#). Res. Microbiol., vol. 165, n° 2, p. 140-153, mars 2014.
 80. Bottero J, Boyd A, Lemoine M, Carrat F, **Gozlan J**, Collignon A, Boo N, Dhotte P, Varsat B, Muller G, Cha O, Valin N, Nau J, Campa P, Silbermann B, Bary M, Girard PM, Lacombe K. [Current state of and needs for hepatitis B screening: results of a large screening study in a low-prevalent, metropolitan region](#). PLoS One. 2014 Mar 24;9(3):e92266.
 81. Matheus S, Pham TB, Labeau B, Huong VT, Lacoste V, Deparis X, **Marechal V**. [Kinetics of dengue non-structural protein 1 antigen and IgM and IgA antibodies in capillary blood samples from confirmed dengue patients](#). Am J Trop Med Hyg. 2014 Mar;90(3):438-43.
 82. Allenbach Y, Chaara W, Rosenzweig M, Six A, Prevel N, Mingozzi F, Wanschitz J, Musset L, Charuel JL, Eymard B, **Salomon B**, Duyckaerts C, Maisonobe T, Dubourg O, Herson S, Klatzmann D, Benveniste O. [Th1 response and systemic Treg Deficiency in inclusion Body myositis](#). PLoS One. 2014 Mar 4;9(3):e88788.
- Feb 2014**
83. **Arnaud L, Mathian A, Haroche J, Gorochov G, Amoura Z**. [Pathogenesis of relapsing polychondritis: a 2013 update](#). Autoimmun Rev. 2014 Feb;13(2):90-5.
 84. Lissina A, **Fastenackels S**, Inglesias MC, Ladell K, McLaren JE, Briceño O, Gostick E, **Papagno L, Autran B, Sauce D**, Price DA, Saez-Cirion A, **Appay V**. [The link between CD8+ T-cell antigen-sensitivity and HIV-suppressive capacity depends on HLA restriction, target epitope and viral isolate](#). AIDS. 2014 Feb 20;28(4):477-86.
 85. Rancan F, Amselgruber S, Hadam S, Munier S, Pavot V, Verrier B, Hackbarth S, **Combadiere B**, Blume-Peytavi U, Vogt A. [Particle-based transcutaneous administration of HIV-1 p24 protein to human skin explants and targeting of epidermal antigen presenting cells](#). J Control Release. 2014 Feb 28;176:115-22.
 86. Hommel B, Charuel JL, **Jaureguiberry S**, Arnaud L, Courtin R, Kassab P, Prendki V, Paris L, Ghillani-Dalbin P, **Thellier M**, Caumes E, **Amoura Z, Mazier D**, Musset L, **Buffet P, Miyara M**. [Chronic malaria revealed by a new fluorescence pattern on the antinuclear autoantibodies test](#). PLoS One. 2014 Feb 13;9(2):e88548.
 87. Guerrera IC, Quetier I, Fetouchi R, Moreau F, Vauloup-Fellous C, **Lekbaby B**, Rousselot C, Chhuon C, Edelman A, Lefevre M, Nicolas JC, **Kremsdorf D**, Lacau Saint Guily J, **Soussan P**. [Regulation of interleukin-6 in head and neck squamous cell carcinoma is related to papillomavirus infection](#). J Proteome Res. 2014 Feb 7;13(2):1002-11..
 88. Seang S, **Boutolleau D, Burrel S**, Regnier S, Epelboin L, Voujon D, Valantin MA, Katlama C, **Agut H**, Caumes E. [Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-](#)

[resistant herpes simplex virus infection](#). nt J STD AIDS. 2014 Feb 17;25(9):676-682.

Jan 2014

89. de Almeida Júnior JN, Figueiredo DS, Toubas D, Del Negro GM, Motta AL, Rossi F, Guitard J, Morio F, Bailly E, Angoulvant A, **Mazier D**, Benard G, **Hennequin C**. [Usefulness of matrix-assisted laser desorption ionisation-time-of-flight mass spectrometry for identifying clinical *Trichosporon* isolates](#). Clin Microbiol Infect. 2014 Aug;20(8):784-90. doi: 10.1111/1469-0691.12502. Epub 2014 Jan 16.
90. Rey J, **Buffet PA**, Ciceron L, Milon G, Mercereau-Puijalon O, Safeukui I. [Reduced erythrocyte deformability associated with hypoargininemia during *Plasmodium falciparum* malaria](#). Sci Rep. 2014 Jan 20;4:3767.
91. **Lescaille G**, Coudert AE, Baaroun V, Ostertag A, Charpentier E, Javelot MJ, Tolédo R, Goudot P, Azérad J, Berdal A, Spano JP, Ruhin B, Descroix V. [Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers](#). Bone. 2014 Jan;58:103-7.
92. Saadoun D, Resche Rigon M, **Thibault V**, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. [PegIFN \$\alpha\$ /ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis](#). J Hepatol. 2015 Jan;62(1):24-30.
93. Touati W, Tran T, Seguin J, Diry M, Flinois JP, Baillou C, Lescaille G, Andre F, Tartour E, **Lemoine FM**, Beaune P, de Waziers I. [A suicide gene therapy combining the improvement of cyclophosphamide tumor cytotoxicity and the development of an anti-tumor immune response](#). Curr Gene Ther. 2014;14(3):236-46.
94. **Vieillard V**, **Baychelier F**, **Debré P**. [NKp44L: A new tool for fighting cancer](#). Oncoimmunology. 2014 Jan 1;3(1):e27988.
95. **Achour A**, **Baychelier F**, Besson C, Arnoux A, Marty M, Hannoun L, Sammuël D, **Debré P**, **Vieillard V** (2014). [Expansion of CMV-mediated NKG2C+ NK cells associates with the development of specific de novo malignancies in liver-transplanted patients](#). J Immunol. 2014 Jan 1;192(1):503-11..
96. Le Garff-Tavernier M, Herbi L, de Romeuf C, Nguyen-Khac F , Davi F, Brissard M, Maloum K, Choquet S, Urbain R, **Vieillard V**, Merle-Béral H. [Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion](#). Leukemia. 2014 Jan;28(1):230-3.
97. **V. Meyssonier**, **T. V. Bui**, **N. Veziris**, **V. Jarlier**, et **J. Robert**, [Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis](#). BMC Infect Dis. 2014 Jan 10;14:18.